Enhanc3D Genomics is a technology company.
Enhanc3D Genomics has raised $16.0M across 2 funding rounds.
Enhanc3D Genomics has raised $16.0M in total across 2 funding rounds.
Enhanc3D Genomics has raised $16.0M in total across 2 funding rounds.
Enhanc3D Genomics's investors include Bioqube Ventures, Business Growth Fund, Parkwalk Advisors.
Enhanc3D Genomics is a biotechnology company developing a proprietary 3D multi-omics platform (GenLink3D™) that maps the spatial organization of the genome to identify causal disease biology, novel therapeutic targets, and biomarkers on a genome-wide scale.[1][2][4] It serves pharmaceutical partners and researchers in drug discovery and precision medicine, solving the challenge of translating vast genetic variant data—especially from non-coding regions—into high-confidence targets for common diseases like autoimmune conditions, cancer, and aging, potentially doubling drug development success rates.[1][2] The company maintains an in-house program focused on autoimmune indications while seeking collaborations, following a £10 million Series A in 2022 that fueled leadership expansion and platform scaling.[1][2]
Enhanc3D Genomics was spun out in 2020 from the Babraham Institute in Cambridge, UK, by academic pioneers Dr. Stefan Schoenfelder and Professor Peter Fraser, experts in 3D genome organization.[1][2] Schoenfelder, who led development of Capture Hi-C technology in Fraser's lab, now serves as Chief Scientific Advisor and group leader at the Institute's Epigenetics Program; Fraser co-founded the company alongside him.[1] The idea emerged from their research unlocking decades of genetic data through 3D mapping, enabling hypothesis-free causal biology insights in relevant cell types—pivotal for expediting target discovery where traditional methods fall short.[1] Early traction included establishing the GenLink3D platform and securing Series A funding in October 2022, which supported operational growth like appointing Hazel Jones as COO.[2]
Enhanc3D Genomics rides the spatial genomics and multi-omics wave, capitalizing on surging genomic data from initiatives like UK Biobank to decode non-coding "dark matter" driving 90%+ of disease variants—critical as traditional 1D sequencing hits limits.[1][2] Timing aligns with AI/ML integration in biotech (e.g., linking enhancers to genes) and precision medicine demand, amid market forces like rising autoimmune prevalence and £multi-billion pharma R&D spends on novel modalities.[1][2][6] It influences the ecosystem by de-risking pipelines for partners, accelerating "from variant to therapy," and enabling blockbuster targets in underserved areas, positioning Cambridge's biotech cluster as a 3D innovation hub.[1][3]
Enhanc3D Genomics is primed for strategic partnerships and pipeline milestones, leveraging its platform to secure pharma deals and advance in-house autoimmune candidates toward preclinical proof.[1][2] Trends like AI-enhanced genomics, single-cell 3D atlases, and regulatory pushes for patient stratification will amplify its edge, potentially yielding first validated targets by 2026-2027. Its influence could expand via acquisitions or IPO as 3D tech becomes standard in drug discovery—transforming genetic data overload into a precision medicine goldmine, much like its founders unlocked the genome's hidden architecture.[1][2]
Enhanc3D Genomics has raised $16.0M across 2 funding rounds. Most recently, it raised $5.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $5.0M Series A | Bioqube Ventures, Business Growth Fund, Parkwalk Advisors | |
| Oct 1, 2022 | $11.0M Series A | Bioqube Ventures, Business Growth Fund, Parkwalk Advisors |